Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC

Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.

Related Keywords

Stephenj Freedland , ,Department Of Urology ,Research In Cancer ,Samuel Oschin Comprehensive Cancer Institute ,Integrated Research ,Law Families Chair ,